Stockwatch: Flat Is The New Black For Lilly And Sanofi

A lackluster fourth-quarter earnings season at least didn't get any worse with the reports of Merck, Lilly, Sanofi and GSK. Flat earnings guidance might be considered to be an improvement on guidance cuts, but financial guidance that depends on currency effects and the absence of generic competition may ultimately be unreliable.

Stockwatch_1200x675
ANDY SMITH GIVES AN INVESTOR'S PERSPECTIVE ON INDUSTRY NEWS

More from Business

More from Scrip